scholarly journals Prevalence of androgen deficiency in aging male in an outpatient population and effects of testosterone gel reposition therapy

Conjecturas ◽  
2021 ◽  
Vol 21 (4) ◽  
pp. 436-447
Author(s):  
Douglas Abdalla ◽  
Victor Ferro Borges ◽  
Michel Hamui Sallum ◽  
Camila Eriane Antunes ◽  
João Arthur Pelegrinelli Thirone ◽  
...  
Keyword(s):  
Muscle Mass ◽  
Visceral Fat ◽  
Laboratory Tests ◽  
Abdominal Circumference ◽  
Total Testosterone ◽  
Androgen Deficiency ◽  
Aging Male ◽  
Testosterone Levels ◽  
Testosterone Gel ◽  
Gel Treatment

Background: Androgen deficiency in aging male (ADAM) is characterized by hypogonadism with symptoms such as reduced sexual desire, muscle mass loss, among others. The treatment with testosterone gel and the results around weight and other indicators are the research objects. Objective: Analysis of association between ADAM and obesity in the outpatient population studied and to verify the outcomes of the testosterone gel treatment. Materials & Methods: From a group of 126 outpatients of University Hospital Mário Palmério, 40 were selected with total testosterone lower than 300ng/dL, upon the signature of written informed consent form and the realization of laboratory tests. After new testosterone dosage and urologic evaluation, 6 patients were treated for an average time of 6 months. Initially the dosage was 50 mg/day, with medical consultations and laboratory tests to verify the effects and to adjust the dosage. The variables analyzed were BMI, abdominal circumference, weight, muscle mass, body and visceral fat, in addition to testosterone serum dosages, lipid profile, amongst others, considering the test t among the beginning and end of treatment, defining the significance level by p<0,05. Results: Significant increase of total testosterone levels (p<0,001) and a tendency of improvement in the free testosterone levels (p=0,061) and no significant reduction of BMI (p=0,4308), abdominal circumference (p=0,1695), weight (p=0,999), body fat (p=0,194) and muscle mass (p=0,632), while visceral fat increased (p=0,5265). Vitamin D had no significant increase (p=0,2422). Conclusion: The total testosterone level was increased after the testosterone gel treatment with statistical significance, however there must be new research with more subjects with ADAM to prove the benefits of this treatment.

Correction of Androgen Deficiency in Men with Type 2 Diabetes

2021 ◽  
Vol 16 ◽  
Author(s):  
Volodymyr Pankiv ◽  
Tetyana Yuzvenko ◽  
Nazarii Kobyliak ◽  
Ivan Pankiv
Keyword(s):  
Type 2 Diabetes ◽  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Control Group ◽  
Total Testosterone ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Testosterone Undecanoate ◽  
Testosterone Levels

Background: In men with low levels of testosterone in the blood, it is believed that the symptoms can be regarded as an association between testosterone deficiency syndrome and related comorbidities. Aim: to investigate the effectiveness of testosterone therapy in patients with type 2 diabetes (T2D) and androgen deficiency. Materials and methods: Testosterone replacement therapy was carried out in 26 men with T2D and clinically or laboratory-confirmed androgen deficiency. The age of the subjects ranged from 35 to 69 years old. Laboratory studies included determinations of the concentration of the hormones estradiol, luteinizing hormone (LH), and prostate-specific antigen (PSA). The observation period was 9 months. Results: The average level of total blood testosterone in the subjects before treatment was 9.4 mol/l and was likely lower than that of the control group (19.3 ± 1.6 nmol/l). The levels of total testosterone in the subjects ranged from 3.9 nmol/l to 10.7 nmol/l, and hormone levels measuring less than 8.0 nmol/l were observed in only 11 patients. After a course of testosterone replacement therapy, a stabilization in total testosterone levels at the level of reference values (as compared to the start of treatment) was observed in the blood of men with T2D after 9 months of observation and the administration of the fourth injection (16.83 ± 0.75 nmol/l). Conclusion: The use of long-acting injectable testosterone undecanoate leads to normalization of total testosterone levels in the blood of men with T2D and androgen deficiency, and LH levels in these patients are unlikely to change.

scholarly journals MY-T study: Symptom-based titration decisions when using testosterone nasal gel, Natesto®

2019 ◽  
Vol 13 (10) ◽  
Author(s):  
Jay Lee ◽  
Gerald Brock ◽  
Jack Barkin ◽  
Nathan Bryson ◽  
Matthew A. Gronski ◽  
...  
Keyword(s):  
Sexual Function ◽  
Adult Male ◽  
Study Endpoint ◽  
Total Testosterone ◽  
Male Hypogonadism ◽  
Androgen Deficiency ◽  
Aging Male ◽  
Normal Range ◽  
Testosterone Therapy ◽  
Symptom Questionnaire

Introduction: Natesto®, testosterone nasal gel (TNG), is a testosterone therapy (TTh) indicated for adult male hypogonadism.1 This study allowed titration decisions to be based on physicians’ assessment of patient symptoms. Methods: Hypogonadal males on active topical testosterone therapy (TThE) or naive to any form of testosterone therapy (TThN) were treated with 22 mg TNG daily (11 mg twice daily) for 90 days. Titration was determined by the physician at Day 90 wherein the dose was increased to 33 mg daily if symptoms were not properly managed. Total testosterone (TT) levels were collected at Day 90 and 120 and the quantitative Androgen Deficiency in the Aging Male (qADAM) symptom questionnaire was administered on Days 0, 30, 60, 90, and 120. Results: At study endpoint, 77.0% of all patients were in the normal TT range. Mean qADAM scores increased from 30.8 at baseline to 35.5 (6.6) at Day 90. Physician assessments resulted in 37% patients being up-titrated for an additional 30 days, however, qADAM scores did not change significantly at the higher dose. Conclusions: The majority of patients achieved the normal range of testosterone with TNG when physicians based their titration decision on an assessment of symptoms. Sexual function and energy-related symptoms were predictive of improvements resulting from treatment. These symptoms were the most relevant indicators for physicians in making decisions relating to titration.

scholarly journals The effectiveness of different regimens of testosterone gel therapy in men with androgen deficiency

2020 ◽  
Vol 10 (1) ◽  
pp. 57-60
Author(s):  
Andrey V. Kuzmenko ◽  
Timur A. Gyaurgiev ◽  
Yulia Yu. Bakutina ◽  
Alena Yu. Zarubayco
Keyword(s):  
Behavioral Therapy ◽  
Control Group ◽  
Total Testosterone ◽  
Androgen Deficiency ◽  
Testosterone Deficiency ◽  
Duration Of Treatment ◽  
Basic Therapy ◽  
Testosterone Gel ◽  
Dose Dependent ◽  
Dose Dependent Effect

The results of androgen replacement therapy with the appointment of a transdermal gel with testosterone in patients with androgen deficiency were presented. 90 men with testosterone deficiency (12 nmol/L) and impaired erectile function were observed. The average age of patients was 58 5.2 years. Patients were divided into 3 groups. Patients of the 1st (control) group underwent basic behavioral therapy, the 2nd group received basic therapy with testosterone gel for a dose of 50 mg, the 3rd group received basic therapy with testosterone gel at a dose of 100 mg. The duration of treatment was 6 months. The use of testosterone in the form of a transdermal gel led to a significant increase in the content of total testosterone in both patients of the 2nd (50 mg) and 3rd groups (100 mg). A dose-dependent effect was noted, in patients of the 3rd group the level of testosterone was significantly higher than in patients 2nd group. An increase in testosterone was accompanied by a decrease in FSH and LH levels.

scholarly journals Prevalence of Symptomatic Androgen Deficiency in Men

2007 ◽  
Vol 92 (11) ◽  
pp. 4241-4247 ◽  
Author(s):  
Andre B. Araujo ◽  
Gretchen R. Esche ◽  
Varant Kupelian ◽  
Amy B. O’Donnell ◽  
Thomas G. Travison ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Free Testosterone ◽  
Population Based ◽  
Total Testosterone ◽  
Androgen Deficiency ◽  
Male Population ◽  
Clinical Criteria ◽  
Testosterone Levels ◽  
Low Testosterone ◽  
Osteoporosis Fracture

Abstract Context: Despite recognition that androgen deficiency in men should be defined according to biochemical and clinical criteria, most prevalence estimates are based on low testosterone levels alone. Objective: The objective of this study was to examine the association between symptoms of androgen deficiency and low total and calculated free testosterone levels and estimate the prevalence of symptomatic androgen deficiency in men. Design: This study was a population-based, observational survey. Participants: A total of 1475 Black, Hispanic, and white men, between the ages of 30–79 yr, with complete data on testosterone, SHBG, and symptoms of androgen deficiency, and who are not taking medications that impact sex steroid levels were randomly selected from the Boston Area Community Health Survey. Outcome: Outcomes were measured as symptomatic androgen deficiency, defined as low total (&lt;300 ng/dl) and free (&lt;5 ng/dl) testosterone plus presence of low libido, erectile dysfunction, osteoporosis or fracture, or two or more of following symptoms: sleep disturbance, depressed mood, lethargy, or diminished physical performance. Results: Mean age of the sample was 47.3 ± 12.5 yr. Approximately 24% of subjects had total testosterone less than 300 ng/dl, and 11% of subjects had free testosterone less than 5 ng/dl. Prevalence of symptoms were as follows: low libido (12%), erectile dysfunction (16%), osteoporosis/fracture (1%), and two or more of the nonspecific symptoms (20%). Low testosterone levels were associated with symptoms, but many men with low testosterone levels were asymptomatic (e.g. in men 50+ yr, 47.6%). Crude prevalence of symptomatic androgen deficiency was 5.6% (95% confidence interval: 3.6%, 8.6%), and was not significantly related to race and ethnic group. Prevalence was low in men less than 70 yr (3.1–7.0%) and increased markedly with age to 18.4% among 70 yr olds. Projection of these estimates to the year 2025 suggests that there will be as many as 6.5 million American men ages 30–79 yr with symptomatic androgen deficiency, an increase of 38% from 2000 population estimates. Conclusions: Prevalence of symptomatic androgen deficiency in men 30 and 79 yr of age is 5.6% and increases substantially with age. The aging of the U.S. male population will cause a large increase in the burden of symptomatic androgen deficiency. Future work should address the clinical significance of low testosterone levels in asymptomatic men.

Variability in total testosterone levels in ageing men with symptoms of androgen deficiency

2010 ◽  
Vol 34 (3) ◽  
pp. 212-216 ◽  
Author(s):  
C. A. Allan ◽  
B. J. G. Strauss ◽  
E. A. Forbes ◽  
E. Paul ◽  
R. I. McLachlan
Keyword(s):  
Total Testosterone ◽  
Androgen Deficiency ◽  
Testosterone Levels
Sign in / Sign up

Export Citation Format

Share Document